Last reviewed · How we verify
YF vaccine (live)
YF vaccine (live) is a live attenuated yellow fever virus vaccine that stimulates both humoral and cellular immune responses to provide protection against yellow fever infection.
YF vaccine (live) is a live attenuated yellow fever virus vaccine that stimulates both humoral and cellular immune responses to provide protection against yellow fever infection. Used for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas.
At a glance
| Generic name | YF vaccine (live) |
|---|---|
| Also known as | YF-VAX vaccine, YF-VAX |
| Sponsor | Sanofi |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a weakened strain of yellow fever virus (17D strain) that replicates in vaccinated individuals but does not cause disease in immunocompetent hosts. This replication triggers robust antibody production and T-cell mediated immunity, conferring long-lasting protection against natural yellow fever virus infection. A single dose typically provides lifelong immunity in most recipients.
Approved indications
- Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas
Common side effects
- Headache
- Myalgia
- Fever
- Injection site reaction
- Fatigue
Key clinical trials
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (PHASE1)
- Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults (PHASE3)
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Durability of Vaccine Responses (PHASE4)
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL (PHASE3)
- Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YF vaccine (live) CI brief — competitive landscape report
- YF vaccine (live) updates RSS · CI watch RSS
- Sanofi portfolio CI